DOI QR코드

DOI QR Code

Efficacy of Oral Administration of Lentinula eododes Mycelia Extract for Breast Cancer Patients Undergoing Postoperative Hormone Therapy

  • Suzuki, Nobutaka (Department of Complementary and Alternative Medicine Clinical R&D, Kanazawa University Graduate School of Medical Science) ;
  • Takimoto, Yuko (Department of Complementary and Alternative Medicine Clinical R&D, Kanazawa University Graduate School of Medical Science) ;
  • Suzuki, Riho (Department of Complementary and Alternative Medicine Clinical R&D, Kanazawa University Graduate School of Medical Science) ;
  • Arai, Takanari (Endowed Center for the Advancement of Pregnancy, Perinatal and Infant Care, Kanazawa University Graduate School of Medical Science) ;
  • Uebaba, Kazuo (Institute of Eastern Medicine, Teikyo Heisei University) ;
  • Nakai, Masuo (Houju Memorial Hospital) ;
  • Strong, Jeffry Michael (Department of Complementary and Alternative Medicine Clinical R&D, Kanazawa University Graduate School of Medical Science) ;
  • Tokuda, Harukuni (Department of Complementary and Alternative Medicine Clinical R&D, Kanazawa University Graduate School of Medical Science)
  • Published : 2013.06.30

Abstract

Extract of Lentinula edodes mycelia (LEM) is currently utilized as an oral biological response modifier (BRM) medicine for cancer patients. However, its effectiveness for breast cancer patients with postoperative adjuvant hormone therapy has not yet been scientifically verified. In this study, we investigated the influence of LEM on the quality of life (QOL) and immune response in breast cancer patients undergoing postoperative adjuvant hormone therapy. Twenty patients were studied in total. They received only hormone therapy in the first 4 weeks followed by hormone therapy and LEM during the next 8 weeks. Laboratory tests, QOL score and peripheral blood cytokine production levels were evaluated during the study period. No changes in QOL or cytokines were noted after the first 4 weeks. In contrast, during the following combined therapy period, improvements were noted in QOL and cytokine levels. Although a future large-scale investigation is necessary to confirm these results, these data suggest that the concomitant use of LEM with postoperative adjuvant hormone therapy improves the QOL and immune function of patients.

Keywords

Lentinula edodes;BRM;breast cancer;hormone therapy;QOL

References

  1. Chihara G, Maeda Y, Hamuro J, et al (1969). Inhibition of mouse sarcoma 180 by polysaccharides from Lentinus edodes (Berk.) sing. Nature, 222, 687-8. https://doi.org/10.1038/222687a0
  2. Fukuhara S, Bito S (1998). Translation, adaptation, and validation of the SF-36 health survey for use in Japan. J Clin Epidemiol, 51, 1037-44. https://doi.org/10.1016/S0895-4356(98)00095-X
  3. Hatam N, Ahmadloo N, Ahmad Kia, et al (2011). Quality of life and toxicity in breast cancer patients using adjuvant TAC (docetaxel, doxorubicin, cyclophosphamide), in comparison with FAC (doxorubicin, cyclophosphamide, 5-fluorouracil). Arch Gynecol Obstet, 284, 215-20. https://doi.org/10.1007/s00404-010-1609-8
  4. Heriot AG (2000). Reduction in cytokine production in colorectal cancer patients: association with stage and reversal by resection. Br J Cancer, 82, 1009-12. https://doi.org/10.1054/bjoc.1999.1034
  5. Itoh A, Isoda K, Kondoh M, et al (2009). Hepatoprotective effect of syringic acid and vanillic acid on concanavalin a-induced liver injury. Biol Pharm Bull, 32, 1215-9. https://doi.org/10.1248/bpb.32.1215
  6. Kornblith AB, Lan L, Archer L, et al (2011). Quality of life of older patients with early-stage breast cancer receiving adjuvant chemotherapy: a companion study to cancer and leukemia group B 49907. J Clin Oncol, 29, 1022-8. https://doi.org/10.1200/JCO.2010.29.9859
  7. Liu M, Li J, Kong F, Lin J, Gao Y (1998). Induction of immunomodulating cytokines by a new polysaccharidepeptide complex from culture mycelia of Lentinus edodes. Immunopharmacology, 40, 187-98. https://doi.org/10.1016/S0162-3109(98)00043-5
  8. McHorney CA, Ware JE Jr, Lu JF et al (1994). The MOS 36- item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care, 32, 40-66. https://doi.org/10.1097/00005650-199401000-00004
  9. Nagashima Y, Sanpei N, Yamamoto S, et al (2005). Evaluation of host immunity and side effects in breast cancer patients treated with adjuvant chemotherapy (FEC therapy). Gan To Kagaku Ryoho, 32, 1550-2.
  10. Ochayon L, Zelker R, Kaduri L, et al (2010). Relationship between severity of symptoms and quality of life in patients with breast cancer receiving adjuvant hormonal therapy. Oncol Nurs Forum, 37, 349-58. https://doi.org/10.1188/10.ONF.349-356
  11. Ohsumi S, Shimozuma K, Ohashi Y, et al (2012). Subjective and objective assessment of edema during adjuvant chemotherapy for breast cancer using taxane-containing regimens in a randomized controlled trial: the national surgical adjuvant study of breast cancer 02. Oncology, 82, 131-8. https://doi.org/10.1159/000336480
  12. Okuno K, Uno K (2011). Efficacy of orally administered Lentinula edodes mycelia extract for advanced gastrointestinal cancer patients undergoing cancer chemotherapy: a pilot study. Asian Pac J Cancer Prev, 12, 1671-4.
  13. Shibata M, Nezu T, Kanou H, et al (2002). Decreased production of interleukin-12 and type 2 immune responses are marked in cachectic patients with colorectal and gastric cancer. J Clin Gastroenterol, 34, 416-20. https://doi.org/10.1097/00004836-200204000-00006
  14. Sisirak V, Faget J, Vey N, et al (2013). Plasmacytoid dendritic cells deficient in IFNalpha production promote the amplification of FOXP3 regulatory T cells and are associated with poor prognosis in breast cancer patients. Oncoimmunology, 2, 22338. https://doi.org/10.4161/onci.22338
  15. Sugano N, Hibino Y, Choji Y, et al (1982). Anticarcinogenic actions of water-soluble and alcohol-insoluble fractions from culture medium of Lentinus edodes mycelia. Cancer Lett, 17, 109-14. https://doi.org/10.1016/0304-3835(82)90022-2
  16. Sugano N, Choji Y, Hibino Y, et al (1985). Anticarcinogenic action of an alcohol-insoluble fraction (LAP1) from culture medium of Lentinus edodes mycelia. Cancer Lett, 27, 1-6. https://doi.org/10.1016/0304-3835(85)90002-3
  17. Tanaka K, Ishikawa S, Matsui Y, et al (2011). Oral ingestion of Lentinula edodes mycelia extract inhibits B16 melanoma growth via mitigation of regulatory T cell-mediated immunosuppression. Cancer Sci, 102, 516-21. https://doi.org/10.1111/j.1349-7006.2010.01841.x
  18. Tanaka K, Ishikawa S, Matsui Y, et al (2012).Combining a peptide vaccine with oral ingestion of Lentinula edodes mycelia extract enhances anti-tumor activity in B16 melanoma-bearing mice. Cancer Immunol Immunother, 61, 2143-52. https://doi.org/10.1007/s00262-012-1275-8
  19. Tanigawa K, Ito Y, Sakai M, et al (2012). Evaluation of quality of life and immune function in cancer patients receiving combined immunotherapy and oral administration of Lentinula edodes mycelia extract. Gan To Kagaku Ryoho, 39, 1779-81.
  20. van Nes JG, Fontein DB, Hille ET, et al (2012). Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side study. Breast Cancer Res Treat, 134, 267-76. https://doi.org/10.1007/s10549-012-2028-2
  21. Yamaguchi Y, Miyahara E, Hihara J (2011). Efficacy and safety of orally administered Lentinula edodes mycelia extract for patients undergoing cancer chemotherapy: a pilot study. Am J Chin Med, 39, 451-9. https://doi.org/10.1142/S0192415X11008956

Cited by

  1. Perception of Patients with Cancer towards Support Management Services and Use of Complementary Alternative Medicine - a Single Institution Hospital-Based Study in Saudi Arabia vol.15, pp.6, 2014, https://doi.org/10.7314/APJCP.2014.15.6.2547
  2. Evaluation of Quality of Life among Patients with Various Types of Cancer Treated with Oral Lentinula Edodes Mycelia Extract vol.14, pp.1, 2017, https://doi.org/10.1625/jcam.14.1
  3. Mushroom Polysaccharides: Chemistry and Antiobesity, Antidiabetes, Anticancer, and Antibiotic Properties in Cells, Rodents, and Humans vol.5, pp.4, 2016, https://doi.org/10.3390/foods5040080
  4. In vitro antitumor activity of Latcripin-15 regulator of chromosome condensation 1 domain protein vol.12, pp.5, 2016, https://doi.org/10.3892/ol.2016.5106
  5. Lentinula edodes mycelia extract plus adjuvant chemotherapy for breast cancer patients: Results of a randomized study on host quality of life and immune function improvement vol.7, pp.3, 2017, https://doi.org/10.3892/mco.2017.1346
  6. Consumption of β-glucans to spice up T cell treatment of tumors: a review vol.18, pp.10, 2018, https://doi.org/10.1080/14712598.2018.1523392